Recognized standard
M24S 2nd Edition
FDA recognition 7-326 · CLSI · InVitro Diagnostics
Key facts
| Recognition number | 7-326 |
|---|---|
| Designation | M24S 2nd Edition |
| Title | Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes |
| Standards developer | Clinical Laboratory Standards Institute |
| Specialty area | InVitro Diagnostics |
| Date of entry | Dec 23, 2024 |
| Device classes | Class 2 |
| Scope (excerpt) | The tables in this document are intended for use with CLSI document M24 that provides protocols and related quality control parameters for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. This document(M24S) includes updated breakpoint and quality control… |
At a glance
- 1–9 Product codes
- 1–9 FDA guidance documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-recognized consensus standards
The FDA recognizes voluntary consensus standards that manufacturers can cite in premarket submissions to show conformity with specific requirements.
Source: U.S. Food and Drug Administration (FDA), Recognized Consensus Standards database · Source date: